Advancing more treatment options for patients

Teva is investing in biopharmaceuticals as part of our long term strategy for the future, and to help patients around the world. We are focusing on treatments for the central nervous system, respiratory conditions, and in the field of oncology.

Biopharmaceuticals are complex medicines made from living cells or organisms. They advance more treatment options for patients, some of whom suffer from untreated or undertreated conditions. They have the potential to deliver precise and personalized treatment.

Biosimilars

Together with creating original biologic medicines, Teva is investing in biosimilars. These are highly similar versions of reference biological treatments. This focus on biosimilars is a natural progression for Teva following our role in the development of the generic medicine industry over the past 100 years. They combine our strength in generics with our knowledge of complex medicine.

Biosimilars offer treatment that is potentially less expensive than the originator biologic but similarly effective. For example, it is estimated that the use of biosimilars will save the US $54 billion over 10 years. 01

The NHS and Biopharmaceuticals

Biosimilar medicines are integral to the National Health Service (NHS). Their use provides significant savings to the NHS and widens access to more medicines for patients earlier.

Biological medicines in particular have revolutionised patient treatment by offering new and effective medicines for acute and chronic conditions including neutropenia, cancer, a wide range of inflammatory and autoimmune diseases, and enzyme or hormone deficiencies.

Biological medicines are the largest cost and growth areas in the NHS medicines budget. To realise greater savings, NHS England wants to drive greater uptake of biosimilars.

By making biosimilar medicines available more quickly, the NHS believes they can take advantage of up to £300 million in savings each year, enabling clinicians to use these savings to allow more patients to have access to other life-saving and life-enhancing treatments.02

The story of biopharmaceuticals

Teva's Steffen Nock takes us on a brief journey through the story of biopharmaceuticals, he charts where biopharmaceuticals came from and where they might be going in the future.

Products and pipeline

Teva has 5 biopharmaceuticals on the market today. In addition, we have approximately 20 original biologic and biosimilar programs in various phases of development, from discovery through to clinical and regulatory stages. 

Many of these treatments will be produced in our new $500 million state-of-the-art biopharmaceutical plant in Ulm, Germany.

The benefit that biopharmaceuticals will bring to patients is what inspires us as we invest in this exciting future. 

Biopharmaceutical innovation will not take place overnight but we are committed to seeing the impact and results of our investment over the next decade.